NanoViricides wins DRC regulatory clearance to start Phase II NV-387 Ebola trial
NNVC•DRC clears Phase II NV-387 trial
NanoViricides secured DRC regulatory clearance to start a Phase II trial of its NV-387 oral gummies for Bundibugyo Ebola.
The study was registered in the Pan African Clinical Trials Registry under ID PACTR202608748555077.
First patient dosing is expected within one to two weeks, with drug supply already delivered to the Ituri site.
